Cynapsus Therapeutics (CYNA) shares have risen sharply in pre-market trading today. The stock has been pushed higher by the announcement of positive results from its Phase 3 dose titration study, CTH-300, assessing APL-130277 for the treatment of OFF episodes in Parkinson's disease (PD) patients. Data from the first 92 subjects showed a 22-point improvement from baseline to 30 minutes in a PD rating scale called MDS-UPDRS Part III. In addition, 60% of patients showed improvement in motor function between five and 12 minutes after dosing, improvement in motor function was maintained beyond 90 minutes and 83% of patients transitioned from OFF to fully ON. CYNA has had a mixed year so far. The stock has seen a recovery since May and year-to-date, it is up just under 4%.